StemRIM (TYO:4599)
Japan · Delayed Price · Currency is JPY 143.00
-5.00 (-3.38%)
Oct 26, 2026, 3:30 PM JST
StemRIM Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
45
Market Cap
8.96B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2026 | - | - | - |
| Jul 31, 2025 | - | - | - |
| Jul 31, 2024 | - | - | - |
| Jul 31, 2023 | 2.35B | 2.33B | 10,581.82% |
| Jul 31, 2022 | 22.00M | -1.38B | -98.43% |
| Jul 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.14B |
| StemCell Institute | 2.81B |
| Immuno-Biological Laboratories | 1.08B |
| AnGes | 962.00M |
| OncoTherapy Science | 777.00M |
| Carna Biosciences | 729.00M |
| Nano Holdings | 202.00M |
| CellSeed | 161.00M |